Physician profile
Deric V Ravsten
NPI 1154431542
$4,806.01
in general payments reported to CMS, 2019-2025
21 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $534 · 2021: $857 · 2022: $870 · 2023: $777 · 2024: $617 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.21 |
| Education | $136.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,087.14 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $668.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $636.55 | 2019-2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $554.48 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $267.88 | 2019-2022 | |
| Alkermes, INC. | $264.42 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.26 | 2020-2025 | Caplyta |
| Allergan, INC. | $233.85 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.70 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $176.08 | 2022-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $109.09 | 2019-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $84.42 | 2024-2025 | Cobenfy |
| Indivior INC. | $62.47 | 2022-2023 | Perseris |
| Lundbeck LLC | $62.04 | 2020-2023 | Rexulti |
| Neuronetics, INC. | $42.92 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.26 | 2021 | |
| Neurocrine Biosciences, INC. | $29.33 | 2023 | Ingrezza |
| Acadia Pharmaceuticals INC | $15.14 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.12 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.26 | 2021 | |
| Merck Sharp & Dohme LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deric Ravsten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.